newsfilter
← Latest News
GlobeNewswire·

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to